News

M30 Apoptosense in NASH Clinical Trials

We are proud to announce that the M30 Apoptosense® ELISA, for use in NASH clinical trials, will be discussed on an Xtalks webinar!

NAFLD is a medical condition characterized by the build-up of fat in the liver and has a spectrum that ranges from steatosis and NASH to fibrotic NASH and cirrhosis. The incidence of NAFLD worldwide is 20-35%, and there are currently no approved drug therapies for NAFLD or NASH.

As biopsy is still the “gold standard” for diagnosis of NASH, non-invasive biomarkers are urgently needed to identify patients and determine their response to novel therapeutic agents.

Markers of hepatic cell death such as keratin 18 (K18) and its caspase-cleaved fragment, ccK18, have been suggested as endpoints for early clinical drug trials. The M30 Apoptosense® ELISA is a specific and reliable tool to measure the concentration of ccK18 fragments. Celerion has validated the M30 Apoptosense® ELISA for use as a secondary endpoint in NASH clinical trials.

Webinar Information

• Monday, October 22, 2018
• 11am EDT (NA)
• 4pm BST (UK)
• 5pm CEST (EU-Central)
• Duration: 60 min

This webinar is sponsored by Diapharma Group, Inc

Click here to register and listen to the free webinar!

EASL – NAFLD SUMMIT 2018

VLVbio will exhibit at the EASL event NAFLD SUMMIT 2018 in Geneve, Switzerland the 20th to 22nd of September.
Meet us there and let us discuss biomarkers!

We will exhibit at The International Liver Congress 2018 in Paris, France.

VLVbio will attend and exhibit at The International Liver Congress in Paris, between the 11th and the 15th of April.

Meet our team members in the exhibition area, and learn about our Keratin 18 biomarker assays.

We will attend the NAFLD Summit EASL event in Rome, Italy November 9-11. Meet our team members from VLVbio and Diapharma Group, Inc. Giannella Coghlan, Adrian Kling and Jessica Tuohy at VLVbio’s space in the exhibition area. Ti vediamo!

We will attend the NAFLD Summit EASL event in Rome, Italy November 9-11.

Meet Ms. Giannella Coghlan from VLVbio together with our American partners Mr. Michael Hambleton, Ms. Jessica Tuohy and Ms. Jennifer Klibinger from DiaPharma Group Inc., at the AASLD booth #543. Grab a coffee with us and let’s talk simple liver disease detection.

Meet us at the AASLD in Washington, The U.S. October 19 – 24th.

Meet us and our partner Biomedica Medizinprodukte in Korcula, Croatia, September 22-24.

Biomedica Medizinprodukte and Mr. Adrian Kling from VLVbio will attend and present at this year’s Congress of the Croatian Gastroenterology Society on the beautiful island Korcula.

On the 24th, around 13.00, Mr. Adrian Kling will hold a presentation about the PEVIVA Product Line and give examples of how these products today are used in the Hepatology field.

If you would like to set up a meeting in advance or would like to reach Mr. Adrian Kling, he is available on adrian.kling@vlvbio.com.

We look forward to seeing you there!